The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 25th 2025
New research reveals how high blood sugar from type 2 diabetes alters brain function, mimicking early Alzheimer symptoms and impacting memory.
Partnership Will Support Collaboration on Health Science Research During COVID-19
December 15th 2020Pharmacy Times® interviewed Signe Pringle, the assistant secretary for the Maryland Department of Commerce, on a signed partnership between Quebec and Maryland to foster collaboration around health science research during COVID-19 and beyond.
Watch
Report: Approval of Pfizer COVID-19 Vaccine Imminent, Distribution Could Begin Monday
December 11th 2020A member of the FDA’s expert advisory committee who voted in favor of Pfizer and BioNTech’s COVID-19 vaccine said that distribution of the first vaccines to high priority populations in the United States could begin as early as Monday.
Read More
The Cardiorenal Benefits, Risks of Treating Type 2 Diabetes With SGLT2 Inhibitors
December 11th 2020There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.
Read More
Fun Fact: What Alcohol-infused Drug Was Used to Treat Plague Victims in the 1600s?
December 11th 2020Paracelsus referred to the drug as the “stone of immortality,” which may have been the impetus for his fine-tuning it further. Later, Thomas Sydenham created his own version in the 1600s with the important addition of alcohol.
Read More
Unfounded Preventions, Treatments for COVID-19 and the Pharmacist Role in Educating the Public
December 11th 2020The objective of the study was to increase awareness among pharmacists about products for which unfounded claims have been made regarding prevention of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections.
Read More
Treatment of Acquired Hemophilia A with Rituximab and Emicizumab
December 9th 2020Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII (FVIII), and the disorder is understudied given its rarity and the lack of randomized prospective trials to guide therapy.
Read More